July 2021

In the next issue of Pharma Technology Focus, we investigate the potential of a malaria vaccine that made headlines earlier this year when a research team from Oxford University announced that it had developed a vaccine candidate that demonstrated 77% effectiveness in early trials. Sticking with vaccines, we take a look at the emerging side-effects of recently approved Covid-19 drugs and the safety of fast-tracked drug approvals.

Elsewhere in the issue, we find out why the use of blood plasma for the production of plasma-derived therapies is controversial in the UK and ask if it is time to rethink the ban, and profile the complex competition considerations that go into reviewing mergers and acquisitions in the pharma industry.

Plus, we examine the challenges that drug manufacturers face in the race to keep up with our changing understanding of mental health and take a look an intravenous treatment for macular degeneration that could provide practitioners with a way to prevent wounds from scarring. All this, plus the latest insight and analysis from GlobalData.

EDITORIAL

Editor | Eloise McLennan

Writers | Abi Millar, Chloe Kent, Natalie Healey, Ahmed Bouzidi
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Maria Gimenez, Filipe Costa, Martina Labaiova​​​, ​Dimeji Akinkuolie, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Relinking the pharma supply chainGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: ILC Dover Go to article: ButterworthGo to article: CommentGo to article: New Chinese Breakthrough Therapy designation attracts foreign companiesGo to article: Endometrial cancer patients expected to benefit from novel advancementsGo to article: Regulatory and strategic complications of marketing an oncology drug in AsiaGo to article: The biopharma revolution: navigating complexityGo to article: TRiBECA KnowledgeGo to article: PerkinElmerGo to article: In DepthGo to article: What’s in a drug name?Go to article: Improving care for rare diseases in IndiaGo to article: Focus on the patient, not the pillGo to article: Academic-industry collaborationGo to article: Rewriting the pharma supply chain for a post-pandemic world Go to article: Developing an oral Covid-19 vaccineGo to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue